IMMUCELL CORP /DE/
About IMMUCELL CORP /DE/
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $27.6M
- Net income
- -$1.0M
- Total assets
- $42.5M
- Market cap
- $86.9M
- Gross margin
- 41.4%
- Operating margin
- 6.0%
- Net margin
- -3.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $27.6M
- Cost of revenue
- $16.2M
- Gross profit
- $11.4M
- Operating expenses
- $9.8M
- Operating income
- $1.6M
- Income tax
- $11.6K
- Net income
- -$1.0M
- EPS (basic)
- $-0.12
- EPS (diluted)
- $-0.12
Balance sheet
- Total assets
- $42.5M
- Current assets
- $16.9M
- Total liabilities
- $15.5M
- Current liabilities
- $4.0M
- Shareholders’ equity
- $27.1M
Cash flow
- Operating cash flow
- $2.5M
- Investing cash flow
- -$1.2M
- Financing cash flow
- -$1.2M
- Net cash flow
- $48.6K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $86.9M
- EPS (diluted)
- $-0.12
- Shares outstanding
- 9.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 8, 1987
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $1.0M in FY2025.
- Revenue grew 44% from FY2021 to FY2025.
- Gross margin of 41.4%, net margin -3.8%.
- Trading 9% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review IMMUCELL CORP /DE/.
Write a review
News about IMMUCELL CORP /DE/
News & sentiment via Polygon.io
